Article
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
All News
Article
The NEJM has published the results of the ACCT-2 Study, a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.
Article
Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.
Article
A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address comparable patient outcomes, implementation strategies and long‐term health system consequences.
Article
The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.
Dr. John Cush
Tweet
RheumNow LIVE VOTE Survey (RHEUMS only):
What Kind of Rheumatologist are You?
General Rheum?
Selective Rheum?
Specialized Rheum?
please vote in our quick 4Q survey https://t.co/2c5fIgcJ5X https://t.co/LgK8yiXEWC
Dr. John Cush
Tweet
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?
Dr. John Cush
Tweet
News Feature: Weight Loss to Avert Risk of Gout
https://t.co/wzf69PvSJc https://t.co/Dph4OAC2Ar
Dr. John Cush
Tweet
2021 Rheumatollgy drugs lead television advertising spending: #1 Humira ($65.8 million); #6 Xeljanz ($33.9 mill); #7 Skyrizi ($40 mill); #8 Enbrel ($25.8mill); #9 Rinvo ($12+ mill) https://t.co/Pan9Vr5kLt
Dr. John Cush
Tweet
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ
Dr. John Cush
Tweet
QD Clinic - I'm Ready to Fly
It's ok to Fly, go to a Resturant and come to https://t.co/9U4LaPKfJs
https://t.co/R0eYO2GiPd https://t.co/Ot9RFlmsVT
Dr. John Cush
Tweet
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians.
Sign up to attend virtually today.
https://t.co/9IGCDMnlrb
Dr. John Cush
Tweet
Comparison of MSU crystal ID, DECT scanning and US to Dx gout - study of 147 pts. Compared to the gold standard (MSU ID), Feet/ankles (87% sensitivity; 100% specificity) or knees DECT (91% & 87%) alone had best Dx accuracy. US was inferior to DECT. https://t.co/h8ctkfeadZ
Dr. John Cush
Tweet
News Feature: Paucity of Effectiveness Research on Telemedicine in RA
https://t.co/AoKnIZCYgA https://t.co/MCBfVoEvBX
Dr. John Cush
Tweet
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i
Dr. John Cush
Tweet
We are just weeks away from RheumNow Live--will you be attending?
https://t.co/vJlU0Z3Q3x https://t.co/i1BhS4JQgi
Dr. John Cush
Tweet
QD Clinic - Don't Stop Believin'
Rheumatic Patients Should NOT Stop DMARDs if the get COVID-19
https://t.co/0JAqwbatn0 https://t.co/3dzU1HHm5e
Dr. John Cush
Tweet
News Feature: Combo Therapy Boosts Response in Uncontrolled Gout
https://t.co/K6tmYWqDCg https://t.co/Li9fcLnP4f
Dr. John Cush
Tweet
GSKs RCT showed otilimab (investigational anti-GM-CSF Ab) in severe COVID-19, was not superior to SOC for the primary endpoint - the proportion alive and free of respiratory failure at 28 days (but was effective in pts >70 yrs (65% vs 46%) https://t.co/OHvWGGlgKv
Dr. John Cush
Tweet
620 RA patients from Nordic biologics registers started a non-TNFi as 1steverr bDMARD but later switched to a 2nd bDMARD (ABA 86, RTX 40, TCZ 67 TNFi 427). Retention was 70% @ 6 mos & 50% @12 mos. 30-40% on 2nd bDMARD reached LDAS or remission https://t.co/u8BQn0rYca
